|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-10-17
|
|
pubmed:abstractText |
Treatment strategies for follicular lymphoma have not been established. We report the outcome after combination therapy with rituximab and cladribine (RC) for 8 patients with follicular lymphoma treated between January 2005 and December 2006 in our hospitals. Median patient age was 57 (range 42 approximately 73) years. There were 4 males and 4 females. Only 1 patient had refractory disease, while the others had untreated disease. On the follicular lymphoma international prognostic index, 4 patients were in the low-risk group, 3 in the intermediate-risk group and 1 in the high-risk group. The median follow-up period was 36 (range 22 approximately 90) weeks. The RC protocol consisted of intravenous rituximab at a dose of 375 mg/m (2) on day 1 and cladribine at a dose of 0.1 mg /kg per day for 2-hours on day 1 through 5. The median number of RC courses was 5 (range 3 approximately 8). The median interval between the 2 courses was 7 (range 3 approximately 26) weeks. The overall response rate was 87.5%. Grade 3 neutropenia was observed in 50% patients, although G-CSF was not needed. There was no apparent thrombocytopenia or anemia. Herpes zoster was observed after treatment in 1 patient. RC is considered highly effective and well tolerated.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
pubmed-author:AkaogiTeruakiT,
pubmed-author:HayashiHideoH,
pubmed-author:HoriikeShigeoS,
pubmed-author:KimuraShinyaS,
pubmed-author:KobayashiYutakaY,
pubmed-author:KurodaJunyaJ,
pubmed-author:MatsumotoYosukeY,
pubmed-author:MurotaniYoshihideY,
pubmed-author:NomuraKenichiK,
pubmed-author:SakoMasamiM,
pubmed-author:SawaiNanaN,
pubmed-author:ShimazakiChihiroC,
pubmed-author:TaniwakiMasafumiM,
pubmed-author:YoshikawaToshikazuT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1623-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17940377-Adult,
pubmed-meshheading:17940377-Aged,
pubmed-meshheading:17940377-Antibodies, Monoclonal,
pubmed-meshheading:17940377-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17940377-Antineoplastic Agents,
pubmed-meshheading:17940377-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17940377-Cladribine,
pubmed-meshheading:17940377-Female,
pubmed-meshheading:17940377-Humans,
pubmed-meshheading:17940377-Lymphoma, Follicular,
pubmed-meshheading:17940377-Male,
pubmed-meshheading:17940377-Middle Aged,
pubmed-meshheading:17940377-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
[Combination therapy with rituximab and cladribine for patients with follicular lymphoma].
|
|
pubmed:affiliation |
Dept. of Hematology and Immunology, Kyoto Second Red Cross Hospital.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
